Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 76

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 76
---
 extension is subject to approval by the USPTO, in conjunction
with the FDA. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply
prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period
or the scope of patent protection afforded could be less than we request. If we are unable to obtain a patent term extension for a given
patent or the term of any such extension is less than we request, the period during which we will have the right to exclusively market
our drug will be that of the originally issued patents themselves.

Even if patents covering one
of our drug candidates are obtained, thereby giving us a period of exclusivity for manufacturing and marketing that drug, we will not
be able to assert such patent rights upon the expiration of the issued patents against potential competitors who may begin marketing generic
copies of our medications, and our business and results of operations may be adversely affected.

Changes in patent law in the United States could diminish the value of patents in general, thereby impairing our ability to protect our drug and diagnostics technology candidates.

The United States has recently
enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope
of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to
increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty
with respect to the value of patents once obtained, if any. Depending on decisions by the U.S. Congress, the federal courts and the USPTO,
the laws and regulations governing patents in the United States could change in unpredictable ways that would weaken our ability to obtain
new patents, or to enforce our existing patents and patents that we might obtain in the future. For example, in a recent case, Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to naturally-occurring substances
are not patentable. Although we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision,
future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patent rights. There could be similar changes
in the laws of foreign jurisdictions that may impact the value of our patent rights or our other IP rights.

In addition, recent patent
reform legislation